<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413580</url>
  </required_header>
  <id_info>
    <org_study_id>GTI1305</org_study_id>
    <nct_id>NCT02413580</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations</brief_title>
  <official_title>A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, open-label, non-controlled study to assess the efficacy
      and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a single dose course of IGIV-C treatment followed by 28-days of
      post-infusion assessments. The total duration of study participation for each subject is up
      to 28 ± 2 days. Approximately 50 subjects, ages 18 or greater, are planned to be enrolled in
      the study and receive a single, total dose of 2 g/kg of IGIV-C over 2 consecutive days (dose
      of 1 g/kg per day) across multiple centers in Argentina, Canada, Europe and South Africa.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative myasthenia gravis (QMG) scale score</measure>
    <time_frame>From Baseline (Day 0) to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical improvement assessed by QMG</measure>
    <time_frame>Baseline (Day 0) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical improvement assessed by MG-Activities of Daily Living (MG-ADL)</measure>
    <time_frame>Baseline (Day 0) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical improvement assessed by the MG Composite</measure>
    <time_frame>Baseline (Day 0) to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Myasthenic Crisis</condition>
  <arm_group>
    <arm_group_label>IGIV-C Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An IV dose of 2 g/kg of IGIV-C will be administered in subjects with myasthenia gravis exacerbations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IGIV-C</intervention_name>
    <description>an IV dose of 2 g/kg of IGIV-C will be administered as 2 doses of 1 g/kg on two consecutive days</description>
    <arm_group_label>IGIV-C Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be willing and able to provide written informed consent (if applicable,
             a legally authorized representative may provide informed consent on behalf of the
             subject).

          -  Subjects who meet the clinical criteria for diagnosis of MG with an exacerbation
             defined as worsening of MG symptoms as defined by an Myasthenia Gravis Foundation of
             America (MGFA) classification IVb or V.

          -  Subjects on long-term (8 weeks) corticosteroid treatment for MG.

          -  Female subjects of child-bearing potential must have a negative test for pregnancy
             (human chorionic gonadotropin [HCG-based assay]).

          -  Subjects must be willing to comply with all aspects of the clinical trial protocol,
             including blood sampling and long-term storage of extra samples, for the entire
             duration of the study.

        Exclusion Criteria:

          -  Subjects who have received immune globulin treatment given by IV, subcutaneous or
             intramuscular route within the last 30 days.

          -  Subjects with documentation of a lack of clinical response to intravenous
             immunoglobulin (IVIg) therapy for MG.

          -  Subjects documented positive for antibodies directed against MuSK.

          -  Subjects with corticosteroid (CS) treatment initiated within the last 8 weeks or
             modified within the last 2 weeks.

          -  Subjects with plasma exchange (PLEX) within the last 30 days.

          -  Subjects with MG exacerbation attributable to change in medication or infection or
             evident infection as defined by, but not limited to, the presence of at least one of
             the following diagnostic features: 1) axillary temperature ≥38°C, 2) positive blood
             culture of infective microorganism, 3) white blood cell count &gt;12×10^9/L and
             differential white blood cell count of &gt;10% band neutrophils (&gt;1.2×10^9/L), and 4)
             pulmonary infiltrate with consolidation on chest X-ray. Alternatively, other signs and
             symptoms may be considered for the diagnosis of evident infection according to the
             Investigator's judgement.

          -  Subjects with inadequate venous access.

          -  Subjects with a history of anaphylactic reactions or severe reactions to any
             blood-derived product.

          -  Subjects with a history of intolerance to any component of the investigational
             products.

          -  Subjects with a documented diagnosis of thrombotic complications to polyclonal IVIG
             therapy in the past.

          -  Subjects with a history of recent (within the last year) myocardial infarction, stroke
             or uncontrolled hypertension.

          -  Subjects who suffer from uncontrolled congestive heart failure, embolism or documented
             electrocardiogram (ECG) changes indicative of myocardial ischemia or atrial
             fibrillation.

          -  Subjects with current known hyperviscosity or hypercoagulable state.

          -  Subjects currently receiving anti-coagulation therapy.

          -  Subjects with a history of chronic alcoholism or illicit drug abuse (addiction) in the
             12 months preceding the Baseline Visit.

          -  Subjects currently receiving, or having received within 3 months prior to the Baseline
             Visit, any investigational medicinal product or device.

          -  Subjects with a known Immunoglobulin A (IgA) deficiency and anti-IgA serum antibodies.

          -  Subjects with renal impairment (i.e., serum creatinine exceeds more than 1.5 times the
             upper limit of normal [ULN] for the expected normal range for the testing laboratory).

          -  Subjects with aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
             levels exceeding more than 2.5 times the ULN for the expected normal range for the
             testing laboratory.

          -  Subjects with haemoglobin levels &lt;9 g/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. J. M.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004CDT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Lucas Gent</name>
      <address>
        <city>Ghent</city>
        <state>East Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network (UHN) - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Neurologicka klinika</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava, Neurologická klinika</name>
      <address>
        <city>Ostrava</city>
        <zip>70800</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <state>Lyon</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-Pesti Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Faculty of Medicine</name>
      <address>
        <city>Szeged</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Korhaz</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni</name>
      <address>
        <city>Bucuresti</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Targu-Mures</name>
      <address>
        <city>Targu Mures</city>
        <zip>RO540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Nizhniy Novgorod region. Nizhniy Novgorod Regional Clinical Hospital named after N.A.Semashko</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Institution of Healthcare. City Multi-field Hospital # 2</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare &quot;Samara Regional Clinical Hospital. V.D.Seredavin</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital,</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

